featured
Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia
Lancet 2021 Feb 02;[EPub Ahead of Print], DY Logunov, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, OV Zubkova, AS Dzharullaeva, AV Kovyrshina, NL Lubenets, DM Grousova, AS Erokhova, AG Botikov, FM Izhaeva, O Popova, TA Ozharovskaya, IB Esmagambetov, IA Favorskaya, DI Zrelkin, DV Voronina, DN Shcherbinin, AS Semikhin, YV Simakova, EA Tokarskaya, DA Egorova, MM Shmarov, NA Nikitenko, VA Gushchin, EA Smolyarchuk, SK Zyryanov, SV Borisevich, BS Naroditsky, AL GintsburgFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.